Introduction
toxicity
Higher plasma and genital HIV-1-RNA concentrations are associated with a higher risk of HIV-1 transmission to serodiscordant partners, with rare transmission rates with plasma HIV-1-RNA below 1500 copies/mL.In recent years, dual therapy with dolutegravir/lamivudine has shown similar virological efficacy to triple therapy based on dolutegravir in treatment-naive people living with HIV (PLWH), with lower cost and, probably, less long-term toxicity.